» Articles » PMID: 38003780

CRP Monitoring in Early Hospitalization: Implications for Predicting Outcomes in Patients with COVID-19

Overview
Journal Pathogens
Date 2023 Nov 25
PMID 38003780
Authors
Affiliations
Soon will be listed here.
Abstract

Elevated C-reactive protein (CRP) levels have been associated with poorer COVID-19 outcomes. While baseline CRP levels are higher in women, obese individuals, and older adults, the relationship between CRP, sex, body mass index (BMI), age, and COVID-19 outcomes remains unknown. To investigate, we performed a retrospective analysis on 824 adult patients with COVID-19 admitted during the first pandemic wave, of whom 183 (22.2%) died. The maximum CRP value over the first five hospitalization days better predicted hospitalization outcome than the CRP level at admission, as a maximum CRP > 10 mg/dL independently quadrupled the risk of death ( < 0.001). Males ( < 0.001) and patients with a higher BMI ( = 0.001) had higher maximum CRP values, yet CRP levels did not impact their hospitalization outcome. While CRP levels did not statistically mediate any relation between sex, age, or BMI with clinical outcomes, age impacted the association between BMI and the risk of death. For patients 60 or over, a BMI < 25 kg/m increased the risk of death ( = 0.017), whereas the reverse was true for patients <60 ( = 0.030). Further impact of age on the association between BMI, CRP, and the risk of death could not be assessed due to a lack of statistical power but should be further investigated.

Citing Articles

Prognostic performance of early immune and endothelial activation markers in mild-to-moderate COVID-19 outpatients: a nested case-control study.

Alemany A, Balanza N, Millat-Martinez P, Ouchi D, Corbacho-Monne M, Morales-Indiano C Front Immunol. 2024; 15:1501872.

PMID: 39664394 PMC: 11631913. DOI: 10.3389/fimmu.2024.1501872.


Inflammatory, Hematological, and Biochemical Biomarkers in COVID-19 Patients.

Ayako R, Patel K, Ndede I, Nordgren J, Larrson M, Mining S Immun Inflamm Dis. 2024; 12(12):e70078.

PMID: 39641395 PMC: 11621974. DOI: 10.1002/iid3.70078.


Evaluation of Salivary Biomarkers and Spirometry for Diagnosing COPD in Non-Smokers and Smokers of Polish Origin.

Rudzinska-Radecka M, Bancerowski B, Marczynski R, Mukherjee D, Sikora T, Morawska K Biomedicines. 2024; 12(6).

PMID: 38927413 PMC: 11200520. DOI: 10.3390/biomedicines12061206.


Clinical courses and outcomes of COVID-19 associated pulmonary aspergillosis in 168 patients with the SARS-CoV-2 omicron variant.

Wang Y, Yao Y, Zhang Q, Chen H, He Y, Hu K BMC Infect Dis. 2024; 24(1):117.

PMID: 38263011 PMC: 10804746. DOI: 10.1186/s12879-023-08971-w.

References
1.
Milenkovic M, Hadzibegovic A, Kovac M, Jovanovic B, Stanisavljevic J, Djikic M . D-dimer, CRP, PCT, and IL-6 Levels at Admission to ICU Can Predict In-Hospital Mortality in Patients with COVID-19 Pneumonia. Oxid Med Cell Longev. 2022; 2022:8997709. PMC: 8884120. DOI: 10.1155/2022/8997709. View

2.
Mueller A, Tamura T, Crowley C, DeGrado J, Haider H, Jezmir J . Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients. Cell Rep Med. 2020; 1(8):100144. PMC: 7598305. DOI: 10.1016/j.xcrm.2020.100144. View

3.
Lapice E, Maione S, Patti L, Cipriano P, Rivellese A, Riccardi G . Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes Care. 2009; 32(9):1734-6. PMC: 2732149. DOI: 10.2337/dc09-0176. View

4.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

5.
Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y . C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020; 92(7):856-862. PMC: 7262341. DOI: 10.1002/jmv.25871. View